Xtant Medical Holdings (XTNT) Price to Sales (2010 - 2025)

Xtant Medical Holdings (XTNT) has reported Price to Sales for 16 consecutive years, with 2.73 the latest figure, recorded in Q3 2025.

• On a quarterly basis, Price to Sales fell 18.59% year-over-year to 2.73 in Q3 2025; TTM through Sep 2025 was 0.68, a 17.09% decrease from a year earlier, with the FY2024 full-year figure at 0.53, down 67.4% from the prior year.
• Price to Sales was 2.73 for Q3 2025 at Xtant Medical Holdings, down from 2.91 in the prior quarter.
• Over five years, Price to Sales peaked at 16.32 in Q1 2021 and troughed at 1.95 in Q4 2024.
• A 5-year average of 4.98 and a median of 4.58 in 2022 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales soared 2621.4% in 2021 and plunged 71.92% in 2022, its largest moves.
• Over 5 years, Price to Sales stood at 3.49 in 2021, then jumped by 34.83% to 4.71 in 2022, then advanced by 11.21% to 5.23 in 2023, then tumbled by 62.65% to 1.95 in 2024, then surged by 39.76% to 2.73 in 2025.
• The last three Price to Sales figures came in at 2.73 (Q3 2025), 2.91 (Q2 2025), and 1.99 (Q1 2025), per Business Quant data.